| Hogdall EV, Christensen L, Kjaer SK, Blaakaer J, Bock JE, Glud E, Norgaard-Pedersen B, Hogdall CK. |
Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. |
Cancer. 2003;98:66-73. |
| Hogdall EV, Kjaer SK, Glud E, Christensen L, Blaakaer J, Vuust J, Bock JE, Norgaard-Pedersen B, Hogdall CK. |
Evaluation of a polymorphism in intron 2 of the p53 gene in ovarian cancer patients. From the Danish "Malova" Ovarian Cancer Study. |
Anticancer Res. 2003;23:3397-404. |
| Hogdall EV, Johansen JS, Kjaer SK, Price PA, Christensen L, Blaakaer J, Bock JE, Glud E, Hogdall CK. |
High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival. |
Oncol Rep. 2003;10:1535-8. |
| Hogdall EV, Hogdall CK, Blaakaer j, Christensen L, Bock JE, Vuust J, Glud E, Kjaer SK. |
K-ras alterations in Danish ovarian tumour patients. From the Danish “Malova” Ovarian Cancer study. |
Gynecol Oncol. 2003;89:31-6. |
| Dehn H, Hogdall EV, Johansen JS, Jorgensen M, Price PA, Engelholm SA, Hogdall CK. |
Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer. |
Acta Obstet Gynecol Scand. 2003;82:287-93. |
| Brinton LA, Kjær SK, Thomsen BL, Sharif H, Graubard B, Olsen JH, Bock JE |
Childhood tumor risk following treatment with ovarian stimulating drugs |
Fertility and Sterility. 2004;81:1083-91. |
| Holten-Andersen MN, Schrohl AS, Brunner N, Nielsen HJ, Hogdall CK, Hogdall EV. |
Evaluation of sample handling in relation to levels of tissue inhibitor of metalloproteinases-1 measured in blood by immunoassay. |
Int J Biol Markers. 2003;18:170-6. |
| Gronlund B, Hansen HH, Hogdall C, Hogdall EV, Engelholm SA. |
Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma? |
Br J Cancer. 2004;90:377-82. |
| Glud E, Kjaer SK, Thomsen BL, Hogdall C, Christensen L, Hogdall E, Bock JE, Blaakaer J. |
Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer. |
Arch Intern Med. 2004;164:2253-9. |
| Hogdall EV, Ryan A, Kjaer SK, Blaakaer J, Christensen L, Bock JE, Glud E, Jacobs IJ, Hogdall CK. |
Loss of heterozygosity on the X chromosome is an independent prognostic factor in ovarian carcinoma. |
Cancer. 2004;100:2387-95. |
| Gronlund B, Hogdall C, Hilden J, Engelholm SA, Hogdall EV, Hansen HH. |
Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma? |
J. Clin Oncol. 2004;22:4051-8. |
| Dicioccio RA, Song H, Waterfall C, Kimura MT, Nagase H, McGuire V, Høgdall E, Shah MN, Luben RN, Easton DF, Jacobs IJ, Ponder BA, Whittemore AS, Gayther SA, Pharoah PD, Kruger-Kjaer S. |
STK15 polymorphisms and association with risk of invasive ovarian cancer. |
Cancer Epidemiol Biomarkers Prev. 2004;13:1589-94. |
| Begum FD, Hogdall CK, Kjaer SK, Christensen L, Blaakaer J, Bock JE, Glud E, Hoyer-Hansen G, Ring-Larsen H, Hogdall EV. |
The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients. |
Anticancer Res. 2004;24:1981-5. |
| Pastrana DV, Buck CB, Pang Y-YS, Thompson CD, Castle PE, Kjær SK, Lowy DR, Schiller JT |
Reactivity of Human Sera in Sensitive High Throughput Pseudovirus Based Neutralization Assays for HPV16 and HPV18 |
Virology. 2004;321: 205-16. |
| Kjær SK, Mellemkjaer L, Brinton LA, Johansen C, Gridley G, Olsen JH |
Tubal sterilization and risk of ovarian, endometrial and cervical cancer. A population-based follow-up study of more than 65 000 sterilized women |
Int J Epidemiol 2004; 33:596-602. |
| Kirschner B, Simonsen K, Junge J, Kjær SK |
Livmoderhalskræft og human papillomavirus. Nye perspektiver inden for screening af livmoderhalskræft |
Månedskr Prakt Lægegern. 2005;83: 923-8. |
| Auranen A, Song H, Waterfall C, Dicioccio RA, Kuschel B, Kjaer SK, Høgdall E, Høgdall C, Stratton J, Whittenmore AS, Easton DF, Ponder BA, Novik KL, Dunning AM, Gayther S, Pharoah PD. |
Polymorphisms in DNA repair genes and epithelial ovarian cancer risk |
Int J Cancer. 2005 May 27; |
| Bøjesen SE, Kjær SK, Høgdall EV, Thomsen BL, Høgdall CK, Blåkær J, Tybjær-Hansen A, Nordestgaard BG |
Increased risk of ovarian Cancer in integrin beta3 Leu33Pro homozygotes |
Endocr Relat Cancer. 2005;12: 945-52. |
| Brinton LA, Sakoda LC, Sherman ME, Frederiksen K, Kjær SK, Graubard BI, Olsen JH, Mellemkjaer L |
Relationship of benign gynecologic diseases to subsequent risk of ovarian and uterine tumors |
Cancer Epidemiol, Biomarkers and Prevention. 2005;14:2929-35. |
| Kjærbye-Thygesen A, Huusom LD, Frederiksen K, Kjaer SK |
Trends in the Incidence and Mortality of Ovarian Cancer in Denmark 1978-2002. Comparison with other Nordic countries |
ACTA. 2005;84:1006-12. |
| Kjaer SK, Munk C, WintherJF, Jørgensen HO, Meijer C, van den Brule A |
Acquisition and persistence of HPV infection in younger men. A prospective follow-up study among Danish soldiers |
Cancer Epidemiol, Biomarkers and Prevention. 2005;14:1528-33. |
| West-Nielsen M, Høgdall EV, Marchiori E, Høgdall CK, Sshou C, Heegaard NH |
Sample handling for mass spectrometric proteomic investigations of human sera |
Anal Chem. 2005;77: 5114-23. |
| International Collaboration of Epidemiological Studies of Cervical Cancer. |
Cervical carcinoma and reproductive factors: Collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 |
Int J Cancer. 2006 Mar 28; [Epub ahead of print] |
| Kyndi M, Frederiksen K, Kjær SK |
Cervical cancer incidence in Denmark over six decades (1943-2002). |
Acta Obstet Gynecol Scand. 2006;85:106-11. |
| Moscicki AB, Schiffman M, Kjaer SK, Villa, LL: |
Chapter 5: Updating the natural history of HPV and anogenital cancer. |
Vaccine. 2006 Aug 21;24 Suppl 3:S42-51. Epub 2006 Jun 23. |
| Kjaer S, Høgdall E, Frederiksen K, Munk C, Van den Brule A, Svare E, Meijer C, Lorincz A, Iftner T. |
The absolute risk of cervical abnormalities in high-risk HPV positive, cytologically negative women over a 10 year period. |
Cancer Res. 2006 Nov 1;66(21):10630-6. Epub 2006 Oct 23. |
| Kjær SK, Olesen F, Toftager-Larsen K, Sand C, Strauss GI, Hoffmann TU, Ottesen BS |
The first HPV vaccine is now available |
Ugeskr Laeger. 2006;168:3827-8. |
| Kjær SK |
Vaccine against human papillomavirus |
Ugeskr Læg 2006;12:1218. |
| Tolstrup JS, Munk C, Thomsen B, Svare E, van den Brule AJC, Grønbæk M, Meijer C, Kjær SK |
The role of smoking and alcohol intake in the development of HSIL among high-risk HPV positive women |
Acta Obstet Gynecol Scand. 2006;85:1114-9. |
| Soegaard M, Kjaer SK, Gayther S. |
Ovarian cancer and genetic susceptibility in relation to the BRCA1 and BRCA2 genes. Occurrence, clinical importance and intervention. |
Acta Obstet Gynecol Scand. 2006:93-105. |
| Kjærbye-Thygesen A, Frederiksen K, Høgdall EV, Glud E, Christensen L, Høgdall CK, Blaakjaer J, Kjaer SK |
Smoking and overweight: negative prognostic factors in stage III epithelial ovarian cancer. |
Cancer Epidemiol Biomarkers Prev. 2006;15:798-803. |
| Kjærbye-Thygesen A, Frederiksen K, Høgdall EV, Høgdall CK, Blaakjaer J, Kjaer SK |
Do risk factors for epithelial ovarian cancer have an impact on prognosis? Focus on previous pelvic surgery and reproductive variables. |
Eur J Gyn Oncol 2006;XXVII:467-472 |
| Høgdall EV, Kjær SK, Blaakær J, Christensen L, Glud E, Vuust J, Høgdall C |
P53 mutations in tissue from Danish ovarian cancer patients: from the Danish MALOVA ovarian cancer study |
Gynecol. Oncol. 2006;100:76-82. |
| Petri AL, Høgdall E, Christensen IJ, Kjær SK, Blåkær J, Høgdall C |
Preoperative CA125 as a prognostic factor in stage I epithelial ovarian cancer |
Apmis. 2006;114: 359-63. |
| Song H, Ramus SJ, Quaye L, Dicioccio RA, Tyrer J, Lomas E, Shadford D, Høgdall E, McGuire V, Whittemore AS, Easton DF, Ponder BA, Kjær SK, Pharoah PD, Gayther SA. |
Common variants in mismatch repair genes and risk of invasive ovarian cancer |
Carcinogenesis 2006 Jun 13: |
| Huusom LD, Frederiksen K, Høgdall EV, Glud E, Christensen L, Høgdall C, Blåkær J, Kjær SK. |
Association of reproductive factors, oral contraceptive use and selected lifestyle factors with the risk of ovarian borderline tumors: a Danish case-control study. |
Cancer Causes Control. 2006;17: 821-9. |
| Begum FD, Høgdall EV, Riisbro R, Christensen IJ, Engelholm SA, Jørgensen M, Pedersen BN, Høgdall CK. |
Prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) in Danish patients with recurrent epithelial ovarian cancer (REOC) |
APMIS. 2006;114: 675-81. |
| Grønlund b, Høgdall EV, Christensen IJ, Johansen JS, Nørgård-Pedersen B, Engelholm SA, Høgdall C |
Pre-treatment prediction of chemorestistance in second-line chemotherapy of ovarian cancer: value of serological tumor marker determination (tetranectin, YKL-40, CASA, CA125) |
Int J Biol Markers. 2006;21:141-8. |
| Høgdall E, Christensen L, Kjær SK, Blaakær J, Kjærbye-Thygesen A, Gayther S, Jacobs IJ, Høgdall C. |
CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumour patients. |
Gynecol Oncol 2006 |
| Song H, Ramus SJ, Shadforth D, Quaye L, Kru¨ger SK, Dicioccio RA, Dunning AM, Hogdall e, Hogdall C, Whittemore A, McGuire V, Lesueur F, Easton DF, Jacobs I, Ponder BA, Gayther S, Pharoah PD. |
Common variants in RB1Gene and risk of invasive ovarian cancer |
Cancer Research. 2006;66:10220-6. |
| Gayther SA, Song H, Ramus SJ, Kjaer SK, Whittermore A, Quaye L,Tyre J, Shadforth D, Hogdall E, Hogdall C, Blaakaer J, DiCioccio R, McGuire V, Webb V, Beesley J, Green AD, Whiteman DC, The Australian Cancer Study (Ovarian Cancer), Goodman MT, Lurie G, Car |
Tagging Single Nucleotide Polymorphisms In Cell Cycle Control Genes And Susceptibility To Invasive Epithelial Ovarian Cancer. |
Cancer Research |
